Navigation Links
UW-Madison spinoff Pedrus finds more to business planning than good science

Pedrus Pharma, a University of Wisconsin-Madison spinout that has sped to the finals in the Governor's Business Plan Contest, may put a stop to the annual flu vaccine hoopla, among other things.

Founders Curtis Brandt and Hansi Dean, both UW-Madison researchers, are developing two drugs based on antiviral peptides discovered in Brandt's lab.......

Full article >>> ration papers were just filed last month."

The company


Pedrus, an acronym of Peptide Drug Strategies, is a drug-discovery company. After taking its first two drugs through trials, it may go on to develop others.

"It turns out that bigger pharmaceutical companies are basically wanting to see a compound get either to the start of phase one or through the phase one clinical ......

Full article >>> st 4-5 years of the company, which we hope will keep the costs down," Brandt said.

The pre-clinical trials, and all of the other development that Pedrus Pharma will be doing with its drug compounds, will need major funding. With eligibility as a company established, Brandt and Dean decided to apply for the Governor's Business Plan Contest because it gave them extra impetus to come up with......

Full article >>>
'"/>

Source:wistechnology.com By Katy Williams 04/18/05


Related biology technology :

1. UW-Madison to receive $125M for bioenergy research center
2. Three finalists named for UW-Madison CIO
3. UW-Madison launches new high-speed research network
4. UW-Madison approves new research institute
5. UW-Madison dean predicts bio-economy will fuel Wisconsin
6. Scott Converse, UW-Madison School of Business, on the innovation mind-set
7. Scott Converse, UW-Madison School of Business, on IT workforce development
8. UW-Madisons Beebe wins scientific award
9. UW-Madison MBA program ranked among best for investment return
10. UW-Madison gets $333,000 for biofuels research
11. UW-Madison enters Kauffman grant competition
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):